Naltrexone (Standard)

Naltrexone (Standard)

• CAS Number: 16590-41-3
• UNSPSC Description: Naltrexone (Standard) is the analytical standard of Naltrexone. This product is intended for research and analytical applications. Naltrexone is an antagonist of Opioid receptor. Naltrexone inhibits cell proliferation in vivo. Naltrexone reduces tumor growth by interfering with cell signalling and modifying the immune system[1].
• Target Antigen: Opioid Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/naltrexone-standard.html
• Smiles: OC1=CC=C2C3=C1O[C@](C(CC4)=O)([H])[C@@]3(CCN5CC6CC6)[C@]4(O)[C@@]5([H])C2
• Molecular Weight: 341.40
• References & Citations: [1]Lobmaier PP, et al. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther. 2011 Dec;17(6):629-36.|[2]Mannelli P, Peindl KS, Wu LT. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Subst Abuse Rehabil. 2011 Jun;2011(2):113-123.|[3]Swift R, Oslin DW, Alexander M, Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs. 2011 Nov;72(6):1012-8.|[4]Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2011;4(6):489-94.|[5]Hulse GK. Improving Clinical Outcomes for Naltrexone as a Management of Problem Alcohol Use. Br J Clin Pharmacol. 2012 Sep 5. doi: 10.1111/j.1365-2125.2012.04452.x.|[6]Naltrexone|[7]Couto RD, et al. Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer. Curr Drug Res Rev. 2021;13(2):86-89.
• Shipping Conditions: Room temperature